An arthritis drug that was being closely watched for its potential use against COVID-19 has delivered disappointing results in clinical trials, its makers said Monday. Kevzara, which is made by Regeneron and Sanofi, does not attack the novel coronavirus but instead inhibits an abnormal immune response called a “cytokine storm” that causes the lungs of the sickest patients to become …
Read More »Closely watched arthritis drug disappoints in COVID-19 trial
April 28, 2020